Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
[Clinical research in private sector: Which strategic analysis?].
Cancer Radiother. 2023 Sep;27(6-7):469-473. doi: 10.1016/j.canrad.2023.06.023. Epub 2023 Aug 16.
Cancer Radiother. 2023.
PMID: 37596122
French.
[Real world data in radiotherapy: A data farming project by Unitrad].
Guihard S, Piot M, Issoufaly I, Giraud P, Bruand M, Faivre JC, Eugène R, Liem X, Pasquier D, Lamrani-Ghaouti A, Ghannam Y, Ruffier A, Guilbert P, Larnaudie A, Thariat J, Rivera S, Clavier JB.
Guihard S, et al. Among authors: lamrani ghaouti a.
Cancer Radiother. 2023 Sep;27(6-7):455-459. doi: 10.1016/j.canrad.2023.06.016. Epub 2023 Jul 29.
Cancer Radiother. 2023.
PMID: 37517975
Review.
French.
Item in Clipboard
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Blay JY, Chevret S, Le Cesne A, Brahmi M, Penel N, Cousin S, Bertucci F, Bompas E, Ryckewaert T, Soibinet P, Boudou-Rouquette P, Saada Bouzid E, Soulie P, Valentin T, Lotz JP, Tosi D, Neviere Z, Cancel M, Ray-Coquard I, Gambotti L, Legrand F, Lamrani-Ghaouti A, Simon C, Even C, Massard C.
Blay JY, et al. Among authors: lamrani ghaouti a.
Lancet Oncol. 2023 Aug;24(8):892-902. doi: 10.1016/S1470-2045(23)00282-6. Epub 2023 Jul 7.
Lancet Oncol. 2023.
PMID: 37429302
Clinical Trial.
Item in Clipboard
A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
Gravis G, Marino P, Olive D, Penault-LLorca F, Delord JP, Simon C, Lamrani-Ghaouti A, Sabatier R, Ciccolini J, Boher JM.
Gravis G, et al. Among authors: lamrani ghaouti a.
BMC Cancer. 2023 May 2;23(1):393. doi: 10.1186/s12885-023-10881-8.
BMC Cancer. 2023.
PMID: 37131154
Free PMC article.
Item in Clipboard
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas.
Toulemonde E, Chevret S, Battistella M, Neidhardt EM, Nardin C, Le Du F, Meyer N, Véron M, Gambotti L, Lamrani-Ghaouti A, Jamme P, Chaffaut C, De Pontville M, Saada-Bouzid E, Beylot-Barry M, Simon C, Jouary T, Marabelle A, Mortier L.
Toulemonde E, et al. Among authors: lamrani ghaouti a.
Cancer Immunol Immunother. 2023 Aug;72(8):2649-2657. doi: 10.1007/s00262-023-03449-9. Epub 2023 Apr 17.
Cancer Immunol Immunother. 2023.
PMID: 37067554
Free PMC article.
Item in Clipboard
Acute skin toxicity of conventional fractionated versus hypofractionated radiotherapy in breast cancer patients receiving regional node irradiation: the real-life prospective multicenter HYPOBREAST cohort.
Bruand M, Salleron J, Guihard S, Crety CM, Liem X, Pasquier D, Lamrani-Ghaouti A, Charra-Brunaud C, Peiffert D, Clavier JB, Desandes E, Faivre JC.
Bruand M, et al. Among authors: lamrani ghaouti a.
BMC Cancer. 2022 Dec 16;22(1):1318. doi: 10.1186/s12885-022-10402-z.
BMC Cancer. 2022.
PMID: 36526987
Free PMC article.
Item in Clipboard
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
Véron M, Chevret S, Grob JJ, Beylot-Barry M, Saiag P, Fléchon A, You B, Maubec E, Jouary T, Toulemonde E, Jamme P, Gambotti L, Lamrani-Ghaouti A, Dupuy A, Lebbe C, Seguin NB, Houede N, Leccia MT, Le Du F, de Pontville M, Gaudy-Marquestre C, Guillot B, Simon C, Marabelle A, Mortier L.
Véron M, et al. Among authors: lamrani ghaouti a.
Eur J Cancer. 2022 Dec;177:103-111. doi: 10.1016/j.ejca.2022.09.013. Epub 2022 Oct 11.
Eur J Cancer. 2022.
PMID: 36335780
Clinical Trial.
Item in Clipboard
PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon.
Rousseau B, Bieche I, Pasmant E, Hamzaoui N, Leulliot N, Michon L, de Reynies A, Attignon V, Foote MB, Masliah-Planchon J, Svrcek M, Cohen R, Simmet V, Augereau P, Malka D, Hollebecque A, Pouessel D, Gomez-Roca C, Guimbaud R, Bruyas A, Guillet M, Grob JJ, Duluc M, Cousin S, de la Fouchardiere C, Flechon A, Rolland F, Hiret S, Saada-Bouzid E, Bouche O, Andre T, Pannier D, El Hajbi F, Oudard S, Tournigand C, Soria JC, Champiat S, Gerber DG, Stephens D, Lamendola-Essel MF, Maron SB, Diplas BH, Argiles G, Krishnan AR, Tabone-Eglinger S, Ferrari A, Segal NH, Cercek A, Hoog-Labouret N, Legrand F, Simon C, Lamrani-Ghaouti A, Diaz LA, Saintigny P, Chevret S, Marabelle A.
Rousseau B, et al. Among authors: lamrani ghaouti a.
Cancer Discov. 2022 Jun 2;12(6):1435-1448. doi: 10.1158/2159-8290.CD-21-0521.
Cancer Discov. 2022.
PMID: 35398880
Free PMC article.
Item in Clipboard
Cite
Cite